Some recent studies suggest as therapeutic agents disease-modifying osteoarthritis drugs (DMOAD) [21,22] and some targeting therapies against inflammatory mediators such as IL1, IL6, or TNFα [23,24,25]; however, they are not officially recognized. This evidence concerns the gene TNF and osteoarthritis.